Andrei V Gudkov

List of Publications by Year
in descending order

192 papers	16,836 citations	12303 69 h-index	16127 124 g-index
198 all docs	198 docs citations	198 times ranked	19962 citing authors

#	Article	IF	Citations
1	A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy. Science, 1999, 285, 1733-1737.	6.0	1,177
2	An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models. Science, 2008, 320, 226-230.	6.0	606
3	The role of p53 in determining sensitivity to radiotherapy. Nature Reviews Cancer, 2003, 3, 117-129.	12.8	510
4	Structural Basis of TLR5-Flagellin Recognition and Signaling. Science, 2012, 335, 859-864.	6.0	454
5	Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene, 2002, 21, 6017-6031.	2.6	333
6	Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene, 2001, 20, 147-155.	2.6	332
7	Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nature Chemical Biology, 2006, 2, 474-479.	3.9	320
8	LINE1 Derepression in Aged Wild-Type and SIRT6-Deficient Mice Drives Inflammation. Cell Metabolism, 2019, 29, 871-885.e5.	7.2	299
9	The candidate tumour suppressor p33ING1cooperates with p53 in cell growth control. Nature, 1998, 391, 295-298.	13.7	284
10	The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging, 2010, 2, 344-352.	1.4	281
11	Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nature Genetics, 1996, 14, 415-420.	9.4	279
12	Paradoxical suppression of cellular senescence by p53. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9660-9664.	3.3	266
13	Regulation of NF-Î°B by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 46-51.	3.3	265
14	Core circadian protein CLOCK is a positive regulator of NF-Î°Bâ€“mediated transcription. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2457-65.	3.3	262
15	Aging of mice is associated with p16(Ink4a)- and Î²-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. Aging, 2016, 8, 1294-1315.	1.4	261
16	Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-ÂB-dependent mechanism of p53 suppression in tumors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17448-17453.	3.3	257
17	Transgenic mice with p53-responsive lacZ: p53activity varies dramatically during normal development and determines radiation and drug sensitivity invivo. EMBO Journal, 1997, 16, 1391-1400.	3.5	251
18	p16(Ink4a) and senescence-associated Î²-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Aging, 2017, 9, 1867-1884.	1.4	244

#	Article	IF	Citations
19	From The Cover: Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3407-3412.	3.3	231
20	p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E89-98.	3.3	229
21	Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene, 2004, 23, 3265-3271.	2.6	222
22	Cells exhibiting strong p16 ^{INK4a} promoter activation in vivo display features of senescence. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2603-2611.	3.3	218
23	p53 is a suppressor of inflammatory response in mice. FASEB Journal, 2005, 19, 1030-1032.	0.2	212
24	BMAL1-dependent circadian oscillation of nuclear CLOCK: posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. Genes and Development, 2003, 17, 1921-1932.	2.7	211
25	Curaxins: Anticancer Compounds That Simultaneously Suppress NF-Î²B and Activate p53 by Targeting FACT. Science Translational Medicine, 2011, 3, 95ra74.	5.8	199
26	Pseudo-DNA damage response in senescent cells. Cell Cycle, 2009, 8, 4112-4118.	1.3	188
27	Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood, 2007, 109, 3803-3811.	0.6	185
28	Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3. Cancer Research, 2006, 66, 3169-3176.	0.4	180
29	Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6302-6307.	3.3	171
30	Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 10309-10314.	3.3	165
31	Inflammation and p53: A Tale of Two Stresses. Genes and Cancer, 2011, 2, 503-516.	0.6	156
32	Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13314-13318.	3.3	154
33	c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene, 2008, 27, 1905-1915.	2.6	144
34	Weak p53 permits senescence during cell cycle arrest. Cell Cycle, 2010, 9, 4323-4327.	1.3	143
35	Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene, 1998, 17, 1089-1096.	2.6	140
36	Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/âˆ’ mice. Aging, 2012, 4, 709-714.	1.4	139

#	Article	IF	Citations
37	AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene, 2002, 21, 3532-3540.	2.6	132
38	Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance and cell immortalization.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3744-3748.	3.3	130
39	Prospective therapeutic applications of p53 inhibitors. Biochemical and Biophysical Research Communications, 2005, 331, 726-736.	1.0	129
40	Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19392-19396.	3.3	128
41	Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 3231-3235.	3.3	127
42	Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes and Development, 2002, 16, 2923-2934.	2.7	127
43	Genome-wide adaptive complexes to underground stresses in blind mole rats Spalax. Nature Communications, 2014, 5, 3966.	5.8	124
44	Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene, 2001, 20, 2587-2599.	2.6	122
45	9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-ÎºB and p53 pathways. Oncogene, 2009, 28, 1151-1161.	2.6	122
46	A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes and Development, 2006, 20, 236-252.	2.7	120
47	Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Science Translational Medicine, 2015, 7, 312ra176.	5.8	120
48	Poliovirus Protein 3A Inhibits Tumor Necrosis Factor (TNF)-Induced Apoptosis by Eliminating the TNF Receptor from the Cell Surface. Journal of Virology, 2001, 75, 10409-10420.	1.5	119
49	Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1857-66.	3.3	112
50	Different impact of p53 and p21 on the radiation response of mouse tissues. Oncogene, 2000, 19, 3791-3798.	2.6	111
51	Association of Mycoplasma hominis infection with prostate cancer. Oncotarget, 2011, 2, 289-297.	0.8	110
52	Differential Association of Products of Alternative Transcripts of the Candidate Tumor Suppressor ING1 with the mSin3/HDAC1 Transcriptional Corepressor Complex. Journal of Biological Chemistry, 2001, 276, 8734-8739.	1.6	109
53	Toll-like Receptor 5 Agonist Protects Mice From Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 228-234.	0.4	104
54	Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1668-E1677.	3.3	104

#	Article	IF	Citations
55	New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53â^'/â^' mice by delaying carcinogenesis. Aging, 2012, 4, 715-722.	1.4	102
56	Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9585-9590.	3.3	100
57	Small-Molecule Multidrug Resistanceâ€"Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma. Cancer Research, 2009, 69, 6573-6580.	0.4	100
58	p53 Inhibitor Pifithrin Î± Can Suppress Heat Shock and Glucocorticoid Signaling Pathways. Journal of Biological Chemistry, 2003, 278, 15465-15468.	1.6	98
59	Identification of Granulocyte Colony-Stimulating Factor and Interleukin-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 497-508.	1.3	97
60	Proteolytic Cleavage of the p65-RelA Subunit of NF-ÎºB during Poliovirus Infection. Journal of Biological Chemistry, 2005, 280, 24153-24158.	1.6	96
61	Pathologies Associated with the p53 Response. Cold Spring Harbor Perspectives in Biology, 2010, 2, a001180-a001180.	2.3	96
62	p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism. Cancer Research, 2004, 64, 1951-1958.	0.4	95
63	Secreted transforming growth factor Â2 activates NF-ÂB, blocks apoptosis, and is essential for the survival of some tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7112-7117.	3.3	91
64	Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8 ⁺ T-cell axis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E874-83.	3.3	86
65	Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget, 2011, 2, 209-221.	0.8	82
66	p53 and the Carcinogenicity of Chronic Inflammation. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026161.	2.9	79
67	Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 14078-14083.	3.3	75
68	Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFÎºB. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16339-16344.	3.3	74
69	p53 Involvement in the Control of Murine Hair Follicle Regression. American Journal of Pathology, 2001, 158, 1913-1919.	1.9	73
70	Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors 2 2Abbreviations: CP, cyclophosphamide; PFT, pifithrin-Î± or p53 inhibitor; HT, hyperthermia; HS, heat shock; HO, hypoxia; and HIF-1, hypoxia inducible factor.. Biochemical Pharmacology, 2001, 62, 657-667.	2.0	73
71	Mycoplasma infection suppresses p53, activates NF-ÎºB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene, 2008, 27, 4521-4531.	2.6	69
72	Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15154-15159.	3.3	69

#	Article	IF	Citations
73	Involvement ofMDR1 P-glycoprotein in multifactorial resistance to methotrexate. , 1996, 65, 613-619.		68
74	p53 is involved in tumor necrosis factor-Î±-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Oncogene, 2000, 19, 1959-1968.	2.6	68
75	Cellular quiescence caused by the Mdm2 inhibitor Nutlin-3A. Cell Cycle, 2009, 8, 3777-3781.	1.3	66
76	Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood, 2010, 115, 1088-1097.	0.6	66
77	Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. Oncogene, 2006, 25, 857-866.	2.6	65
78	Dangerous habits of a security guard: the two faces of p53 as a drug target. Human Molecular Genetics, 2007, 16, R67-R72.	1.4	65
79	Prevention and Mitigation of Acute Radiation Syndrome in Mice by Synthetic Lipopeptide Agonists of Toll-Like Receptor 2 (TLR2). PLoS ONE, 2012, 7, e33044.	1.1	64
80	Radioprotection: smart games with death. Journal of Clinical Investigation, 2010, 120, 2270-2273.	3.9	63
81	CBLB613: A TLR 2/6 Agonist, Natural Lipopeptide ofMycoplasma arginini, as a Novel Radiation Countermeasure. Radiation Research, 2012, 177, 628-642.	0.7	61
82	Structure and Regulation of the Mouse ing1 Gene. Journal of Biological Chemistry, 1999, 274, 32172-32181.	1.6	60
83	Down-Regulation of p53 by Double-Stranded RNA Modulates the Antiviral Response. Journal of Virology, 2005, 79, 11105-11114.	1.5	57
84	p53 Determines Multidrug Sensitivity of Childhood Neuroblastoma. Cancer Research, 2007, 67, 10351-10360.	0.4	57
85	Physiological frailty index (PFI): quantitative in-life estimate of individual biological age in mice. Aging, 2017, 9, 615-626.	1.4	54
86	Forward genetics in mammaliancells: functional approaches to gene discovery. Human Molecular Genetics, 1999, 8, 1925-1938.	1.4	53
87	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochemical Pharmacology, 2014, 91, 97-108.	2.0	53
88	Anti-malaria drug blocks proteotoxic stress response: Anti-cancer implications. Cell Cycle, 2009, 8, 3960-3970.	1.3	52
89	Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2/neu Transgenic Mice. Cancer Prevention Research, 2012, 5, 1025-1035.	0.7	52
90	Inhibition of p53 Response in Tumor Stroma Improves Efficacy of Anticancer Treatment by Increasing Antiangiogenic Effects of Chemotherapy and Radiotherapy in Mice. Cancer Research, 2006, 66, 9356-9361.	0.4	51

#	Article	IF	Citations
91	A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity. PLoS ONE, 2014, 9, e85587.	1.1	51
92	Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit. Nature Communications, 2021, 12, 2765.	5.8	50
93	Could p53 be a target for therapeutic suppression?. Seminars in Cancer Biology, 1998, 8, 389-400.	4.3	48
94	Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene, 2002, 21, 153-157.	2.6	45
95	A Purine Nucleotide Biosynthesis Enzyme Guanosine Monophosphate Reductase Is a Suppressor of Melanoma Invasion. Cell Reports, 2013, 5, 493-507.	2.9	45
96	Paradoxical role of apoptosis in tumor progression. Journal of Cellular Biochemistry, 2003, 88, 128-137.	1.2	44
97	The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates. PLoS ONE, 2015, 10, e0135388.	1.1	44
98	Converting p53 from a killer into a healer. Nature Medicine, 2002, 8, 1196-1198.	15.2	42
99	Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro-Oncology, 2017, 19, now141.	0.6	41
100	Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget, 2014, 5, 802-814.	0.8	41
101	The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget, 2016, 7, 2936-2950.	0.8	40
102	The Bloom syndrome protein interacts and cooperates with p53 in regulation of transcription and cell growth control. Oncogene, 2001, 20, 8276-8280.	2.6	38
103	A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. Cell Cycle, 2010, 9, 1434-1443.	1.3	38
104	Different Effect of Proteasome Inhibition on Vesicular Stomatitis Virus and Poliovirus Replication. PLoS ONE, 2008, 3, e1887.	1.1	38
105	A TLR5 Agonist Inhibits Acute Renal Ischemic Failure. Journal of Immunology, 2011, 187, 3831-3839.	0.4	37
106	Combined Stimulation of Toll-Like Receptor 5 and NOD1 Strongly Potentiates Activity of NF-Î¹B, Resulting in Enhanced Innate Immune Reactions and Resistance to Salmonella enterica Serovar Typhimurium Infection. Infection and Immunity, 2013, 81, 3855-3864.	1.0	37
107	OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia, 2020, 34, 1828-1839.	3.3	37
108	Cell transforming genes and tumor progression: In vivo unified secondary phenotypic cell changes. , 1998, 75, 277-283.		36

#	Article	IF	Citations
109	Microarray Analysis of p53-Mediated Transcription: Mutli-Thousand Piece Puzzle or Invitation to Collective Thinking?. Cancer Biology and Therapy, 2003, 2, 444-445.	1.5	35
110	Impact papers on aging in 2009. Aging, 2010, 2, 111-121.	1.4	35
111	Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1. Oncotarget, 2011, 2, 1279-1290.	0.8	35
112	Inhibition of Encephalomyocarditis Virus and Poliovirus Replication by Quinacrine: Implications for the Design and Discovery of Novel Antiviral Drugs. Journal of Virology, 2010, 84, 9390-9397.	1.5	34
113	TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. ELife, 2018, 7, .	2.8	34
114	Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation. Radiation Research, 2017, 187, 570.	0.7	33
115	Elimination of Proliferating Cells Unmasks the Shift from Senescence to Quiescence Caused by Rapamycin. PLoS ONE, 2011, 6, e26126.	1.1	33
116	Dominant Negative Form of Signal-regulatory Protein-Î± (SIRPÎ±/SHPS-1) Inhibits Tumor Necrosis Factor-mediated Apoptosis by Activation of NF-ÎºB. Journal of Biological Chemistry, 2003, 278, 3809-3815.	1.6	32
117	Sensitization of DNA damageâ€“induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3Ïƒ and survivin. Molecular Cancer Therapeutics, 2005, 4, 1880-1890.	1.9	32
118	Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses. PLoS ONE, 2016, 11, e0155650.	1.1	32
119	Quantitative characterization of biological age and frailty based on locomotor activity records. Aging, 2018, 10, 2973-2990.	1.4	32
120	Localization of the candidate tumor suppressor geneING1 to human chromosome 13q34. Somatic Cell and Molecular Genetics, 1997, 23, 233-236.	0.7	31
121	Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. Oncogene, 2003, 22, 4911-4917.	2.6	31
122	Apoptosis Inhibitor as a Suppressor of Tumor Progression: Expression of Bcl-2 Eliminates Selective Advantages for p53-Deficient Cells in the Tumor. Cancer Biology and Therapy, 2002, 1, 39-44.	1.5	30
123	Potent antileukemic activity of curaxin CBL0137 against MLLâ€rearranged leukemia. International Journal of Cancer, 2020, 146, 1902-1916.	2.3	30
124	Histone Methyltransferase KMT1A Restrains Entry of Alveolar Rhabdomyosarcoma Cells into a Myogenic Differentiated State. Cancer Research, 2011, 71, 3921-3931.	0.4	29
125	Poliovirus Protein 3A Binds and Deregulates LIS1, Causing Block of Membrane Protein Trafficking and Deregulation of Cell Division. Cell Cycle, 2005, 4, 1403-1410.	1.3	28
126	Murine mesenchymal cells that express elevated levels of the CDK inhibitor p16(Ink4a)in vivoare not necessarily senescent. Cell Cycle, 2017, 16, 1526-1533.	1.3	28

#	Article	IF	Citations
127	Applications of green fluorescent protein as a marker of retroviral vectors. Somatic Cell and Molecular Genetics, 1997, 23, 325-340.	0.7	27
128	Quinacrine inhibits the epidermal dendritic cell migration initiating T cellâ€mediated skin inflammation. European Journal of Immunology, 2007, 37, 2257-2267.	1.6	27
129	Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate, 2007, 67, 1801-1815.	1.2	27
130	Dysregulation of the mTOR pathway in p53-deficient mice. Cancer Biology and Therapy, 2013, 14, 1182-1188.	1.5	27
131	Functional Genetic Screen for Genes Involved in Senescence: Role of Tid1, a Homologue of the Drosophila Tumor Suppressor l(2)tid , in Senescence and Cell Survival. Molecular and Cellular Biology, 2004, 24, 10792-10801.	1.1	26
132	A TLR5 Agonist Enhances CD8+T Cell-Mediated Graft-versus-Tumor Effect without Exacerbating Graft-versus-Host Disease. Journal of Immunology, 2012, 189, 4719-4727.	0.4	25
133	Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion. Aging, 2012, 4, 917-922.	1.4	24
134	Expression of erbB Receptors and their Ligands in Breast Cancer: Implications to Biological Behavior and Therapeutic Response. Breast Disease, 2000, 11, 63-75.	0.4	22
135	Bisindolylmaleimide IX Facilitates Tumor Necrosis Factor Receptor Family-mediated Cell Death and Acts as an Inhibitor of Transcription. Journal of Biological Chemistry, 2002, 277, 33213-33219.	1.6	22
136	Immune checkpoint protein VSIG4 as a biomarker of aging in murine adipose tissue. Aging Cell, 2020, 19, e13219.	3.0	21
137	Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Reports, 2021, 35, 108994.	2.9	21
138	Isolation of Genetic Suppressor Elements (GSEs) from Random Fragment cDNA Libraries in Retroviral Vectors. , 1997, 69, 221-240.		20
139	Serologically Defined Colon Cancer Antigen 3 Is Necessary for the Presentation of TNF Receptor 1 on Cell Surface. DNA and Cell Biology, 2005, 24, 777-785.	0.9	20
140	Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Cell Cycle, 2009, 8, 4155-4167.	1.3	20
141	Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas. Cancer Research, 2016, 76, 6620-6630.	0.4	20
142	Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. Leukemia, 2020, 34, 1524-1539.	3.3	20
143	Falkor, a novel cell growth regulator isolated by a functional genetic screen. Oncogene, 2002, 21, 6713-6721.	2.6	19
144	Functional genetic screening reveals the role of mitochondrial cytochrome b as a mediator of FAS-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14453-14458.	3.3	19

#	Article	IF	Citations
145	Induction of monoamine oxidase A-mediated oxidative stress and impairment of NRF2-antioxidant defence response by polyphenol-rich fraction of Bergenia ligulata sensitizes prostate cancer cells in vitro and in vivo. Free Radical Biology and Medicine, 2021, 172, 136-151.	1.3	19
146	Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence. Oncogene, 1997, 15, 3007-3012.	2.6	18
147	A review of the biomedical innovations for healthy longevity. Aging, 2017, 9, 7-25.	1.4	18
148	TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. PLoS ONE, 2020, 15, e0227940.	1.1	18
149	Quercetinase Pirin Makes Poliovirus Replication Resistant to Flavonoid Quercetin. DNA and Cell Biology, 2008, 27, 191-198.	0.9	17
150	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene, 2019, 38, 3824-3842.	2.6	17
151	The Ability of Protein Tyrosine Phosphatase SHP-1 to Suppress NFÎºB Can Be Inhibited by Dominant Negative Mutant of SIRPÎ±. DNA and Cell Biology, 2004, 23, 175-182.	0.9	16
152	Peptides genetically selected for NF-ÎºB activation cooperate with oncogene Ras and model carcinogenic role of inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E474-83.	3.3	15
153	Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2017, 64, e26263.	0.8	15
154	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. Clinical Cancer Research, 2021, 27, 4338-4352.	3.2	14
155	Cancer drug discovery: the wisdom of imprecision. Nature Medicine, 2004, 10, 1298-1299.	15.2	13
156	Inhibition of human parainfluenza virus type 3 infection by novel small molecules. Antiviral Research, 2008, 77, 83-94.	1.9	13
157	Latest advances in aging research and drug discovery. Aging, 2019, 11, 9971-9981.	1.4	13
158	A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications. Communications Biology, 2021, 4, 466.	2.0	12
159	CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget, 2016, 7, 46067-46087.	0.8	12
160	Small-Molecule Xenomycins Inhibit All Stages of the Plasmodium Life Cycle. Antimicrobial Agents and Chemotherapy, 2015, 59, 1427-1434.	1.4	11
161	Generation of p53 suppressor peptide from the fragment of p53 protein. Somatic Cell and Molecular Genetics, 1999, 25, 115-128.	0.7	9
162	Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system. Antiviral Research, 2011, 91, 94-98.	1.9	9

#	Article	IF	Citations
163	Stimulation of an anti-tumor immune response with â€œchromatin-damagingâ€•therapy. Cancer Immunology, Immunotherapy, 2021, 70, 2073-2086.	2.0	8
164	Alkaloid-rich fraction of Ervatamia coronaria sensitizes colorectal cancer through modulating AMPK and mTOR signalling pathways. Journal of Ethnopharmacology, 2022, 283, 114666.	2.0	8
165	The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. Frontiers in Oncology, 0, 12, .	1.3	8
166	Development of infrastructure for a systemic multidisciplinary approach to study aging in retired sled dogs. Aging, 2021, 13, 21814-21837.	1.4	7
167	Signaling through TLR5 mitigates lethal radiation damage by neutrophil-dependent release of MMP-9. Cell Death Discovery, 2021, 7, 266.	2.0	7
168	Superior cancer preventive efficacy of low versus high dose of mTOR inhibitor in a mouse model of prostate cancer. Oncotarget, 2020, 11, 1373-1387.	0.8	7
169	Genetic Suppressor Elements in the Characterization and Identification of Tumor Suppressor Genes. , 2003, 222, 413-436.		6
170	Selection-subtraction approach (SSA): A universal genetic screening technique that enables negative selection. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9327-9332.	3.3	6
171	First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients. Oncotarget, 2020, 11, 1273-1288.	0.8	6
172	Distribution of mouse mammary tumor virus-related sequences does not correlate with the taxonomic position of their hosts. Virus Genes, 1990, 4, 85-92.	0.7	4
173	Long terminal repeats of dwarf hamster endogenous retrovirus are highly diverged and do not maintain efficient transcription. Virology, 1991, 181, 367-370.	1.1	4
174	Novel mouse models of hepatic artery infusion. Journal of Surgical Research, 2017, 219, 25-32.	0.8	4
175	In Regard to Schuller etÂal. (Int J Radiat Oncol Biol Phys 2007;68:205â€“210). International Journal of Radiation Oncology Biology Physics, 2008, 70, 800-801.	0.4	2
176	A murine model of targeted infusion for intracranial tumors. Journal of Neuro-Oncology, 2016, 126, 37-45.	1.4	2
177	Isolation of p53 Inhibitors by Screening Chemical Libraries in Cell-Based Readout System. , 2003, 223, 635-648.		1
178	Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. , 1996, 65, 613.		1
179	Introducing, OncoTarget. Oncotarget, 2010, 1, 2-2.	0.8	1
180	Pretreatment of the Cells With Brefeldin A and Cycloheximide Differently Regulates Fas and TNF Stimulated Apoptosis. Scientific World Journal, The, 2001, 1, 40-40.	0.8	0

#	Article	IF	Citations
181	Small Molecule Drugs and Targeted Therapies for Neuroblastoma. , 0, , .		0
182	Resistance of bone marrow stroma to genotoxic preconditioning is determined by p53. Cell Death and Disease, 2021, 12, 545.	2.7	0
183	Cell-Based Methods for the Identification of MYC-Inhibitory Small Molecules. Methods in Molecular Biology, 2013, 1012, 255-264.	0.4	0
184	ATM is activated in blood monocytes after tumor radiation. Oncotarget, 2013, 4, 1125-1125.	0.8	0
185	Abstract PR09: MYCN and is a therapeutic target in neuroblastoma. , 2015, , .		0
186	Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells. Blood, 2015, 126, 1391-1391.	0.6	0
187	Therapeutic Strategies Based on Pharmacological Modulation of p53 Pathway. , 2005, , 225-242.		0
188	TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. , 2020, 15, e0227940.		0
189	TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. , 2020, 15, e0227940.		0
190	TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. , 2020, 15, e0227940.		0
191	TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. , 2020, 15, e0227940.		0
192	Targeted Modulation of Interferon Response-Related Genes with IFN-Alpha/Lambda Inhibition. International Journal of Molecular Sciences, 2022, 23, 7248.	1.8	0